1. Home
  2. NRIX vs TRS Comparison

NRIX vs TRS Comparison

Compare NRIX & TRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nurix Therapeutics Inc. Common stock

NRIX

Nurix Therapeutics Inc. Common stock

HOLD

Current Price

$19.57

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Logo TriMas Corporation

TRS

TriMas Corporation

HOLD

Current Price

$33.78

Market Cap

1.4B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
NRIX
TRS
Founded
2009
1986
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Specialties
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.4B
IPO Year
2020
2007

Fundamental Metrics

Financial Performance
Metric
NRIX
TRS
Price
$19.57
$33.78
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
13
2
Target Price
$26.08
$41.50
AVG Volume (30 Days)
1.8M
837.0K
Earning Date
01-27-2026
10-28-2025
Dividend Yield
N/A
0.48%
EPS Growth
N/A
68.70
EPS
N/A
1.08
Revenue
$83,687,000.00
$1,013,740,000.00
Revenue This Year
$58.38
$11.57
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$30.89
Revenue Growth
48.32
11.83
52 Week Low
$8.18
$19.33
52 Week High
$22.95
$40.34

Technical Indicators

Market Signals
Indicator
NRIX
TRS
Relative Strength Index (RSI) 70.09 49.89
Support Level $16.02 $32.51
Resistance Level $22.50 $34.47
Average True Range (ATR) 1.33 1.01
MACD 0.32 0.26
Stochastic Oscillator 72.19 70.77

Price Performance

Historical Comparison
NRIX
TRS

About NRIX Nurix Therapeutics Inc. Common stock

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

About TRS TriMas Corporation

TriMas Corp designs, develops and manufactures a diverse set of products primarily for the consumer products, aerospace & defense, and industrial markets . The company operates through three segments namely: The packaging segment manufactures and distributes closure and dispensing systems. The aerospace segment supplies blind bolts, fasteners, rivets, and other products for the aerospace industry. The specialty product segment manufactures and distributes steel cylinders, wellhead engines, compression systems, industrial sealing, and fasteners.

Share on Social Networks: